Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort.

Blood Cancer J · 2026 · PMC13128851 · PMID 42056076

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

There is an observed trend toward higher OS in the RI cohort, as not reached (NR) (95% CI: 10.38–NR), compared to the no-RI group of 8.71 months (95% CI: 3.25–NR) (Fig. 1B ).

also in 258 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.